Novavax (NVAX +1.9%) says it's begun enrollment for Phase 1 clinical trials of its A(H7N9)...

|By:, SA News Editor

Novavax (NVAX +1.9%) says it's begun enrollment for Phase 1 clinical trials of its A(H7N9) vaccine candidate for the prevention of avian flu. Research on the drug has progressed rapidly, moving from viral gene sequencing, to vaccine candidacy, to multiple animal studies, and now, just three months after the gene sequence was obtained, into a clinical trial.